Evidence map›Paper›PMID 40486874›Full record

ReviewOncology research2025

Comprehensive review of male breast cancer: Understanding a rare condition.

Abdur Jamil, Rimsha Siddique, Faryal Altaf, Daniyal Warraich, Faizan Ahmed, Zaheer Qureshi

Abstract readReview
In one paragraph

Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Mapping the invisible: a Bayesian spatio-temporal analysis of male breast cancer mortality inequalities across Spanish provinces, 1999-2023.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Abdur JamilDepartment of Medicine, Samaritan Medical Centre, Watertown, NY 13601, USA.
Rimsha SiddiqueIndependent Research Associate, Watertown, NY 13601, USA.
Faryal AltafDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai/BronxCare Health System, New York, NY 10457, USA.
Daniyal WarraichDepartment of Internal Medicine, Sahiwal Medical College, Sahiwal, 57040, Pakistan.
Faizan AhmedDivision of Cardiology, Duke University Hospital, Durham, NC 27710, USA.
Zaheer QureshiDepartment of Internal Medicine, School of Medicine at Quinnipiac University, Bridgeport, CT 06473, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Male breast cancer (MBC) is a rare but significant health concern, accounting for less than 1% of all breast cancer cases. Despite its low incidence, it presents unique clinical, genetic, and psychosocial challenges. Genetic predispositions, including BRCA2 mutations and hormonal imbalances, are key factors influencing the development of MBC. However, the rarity of the condition has led to limited research and fewer treatment guidelines specifically for male patients. Methods: A comprehensive literature review was conducted using PubMed, MEDLINE, and Embase databases to identify studies focusing on the epidemiology, risk factors, clinical presentation, diagnosis, treatment, and psychosocial impacts of male breast cancer. Articles were selected based on relevance, peer-review status, and focus on MBC in male patients. Data were synthesized narratively, and findings were contextualized based on the methodology and design of included studies. Results: The review identified several significant risk factors for MBC, including BRCA2 mutations, hormonal imbalances (particularly estrogen and testosterone levels), and family history of breast cancer. MBC is often diagnosed at later stages due to the absence of routine screening in men, resulting in poorer survival outcomes compared to female breast cancer. Treatment strategies for MBC largely mirror those for women, including surgery, radiation, chemotherapy, and hormonal therapies. However, the psychosocial impacts of MBC are unique to men, with issues such as stigma, body image concerns, and societal perceptions of masculinity. Conclusions: Male breast cancer remains an understudied area of oncology, with significant gaps in research related to early detection, targeted therapies, and long-term care. Collaborative international research efforts, such as the MERGE consortium and the International Male Breast Cancer Program, are essential for improving understanding and treatment outcomes. Genetic counseling, early screening, and personalized treatment approaches are crucial in managing the disease. Further research focusing on the molecular basis of MBC, along with the psychosocial needs of affected men, is necessary to enhance both survival rates and quality of life for male breast cancer patients.

Indexed as

Breast Neoplasms, MaleBRCA2 ProteinGenetic Predisposition to DiseaseHumansMaleMutationRisk FactorsBRCA2 ProteinBRCA2 protein, humanBRCA mutationsGenetic mutationsHormonal imbalanceHormone therapyMale breast cancer (MBC)Survival analysisTargeted therapy

Identifiers

PMID40486874
PMCPMC12144614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.